{"id": "1387370860386918400", "creation": 1619609963.0, "user_id": "621185967", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 2, "quote_count": 0}}, "quoted": "1387158381849423876", "text": "\u201cA crucial issue for the #Brazilian regulator was the risk of other viruses used to make the [#Russian] #vaccine reproducing in patients, which #Anvisa's medicines and biological products manager Gustavo Mendes called a \u2018serious\u2019 defect.\u201d \ud83e\udd14 #COVID19 #compliance #procurement https://t.co/JfI0VDhhRw", "first_save": 1634559108.199414, "hashtags": ["#BRAZILIAN", "#RUSSIAN", "#VACCINE", "#ANVISA", "#COVID19", "#COMPLIANCE", "#PROCUREMENT"]}